Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Woodline Partners LP

Woodline Partners LP cut its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 64.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 567,060 shares of the company's stock after selling 1,037,471 shares during the period. Woodline Partners LP owned about 0.18% of Amneal Pharmaceuticals worth $4,491,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Amneal Pharmaceuticals during the fourth quarter worth approximately $81,000. Straightline Group LLC acquired a new stake in Amneal Pharmaceuticals during the fourth quarter worth approximately $92,000. Brevan Howard Capital Management LP purchased a new stake in shares of Amneal Pharmaceuticals during the 4th quarter worth approximately $107,000. Cibc World Markets Corp purchased a new stake in shares of Amneal Pharmaceuticals during the 4th quarter worth approximately $118,000. Finally, Janney Montgomery Scott LLC acquired a new position in shares of Amneal Pharmaceuticals in the 4th quarter valued at $121,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Gautam Patel sold 80,000 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.90, for a total value of $712,000.00. Following the completion of the sale, the director now owns 1,808,886 shares in the company, valued at approximately $16,099,085.40. This trade represents a 4.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the transaction, the insider now directly owns 48,578,209 shares of the company's stock, valued at $405,628,045.15. This represents a 9.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 26.56% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently commented on AMRX shares. Wall Street Zen lowered shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, May 13th. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $9.00 to $12.00 in a report on Monday, February 24th. Finally, Barclays boosted their target price on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a report on Monday, March 3rd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $11.50.

Amneal Pharmaceuticals Stock Performance

Amneal Pharmaceuticals stock traded up $0.13 during midday trading on Tuesday, hitting $7.29. 1,555,497 shares of the company's stock were exchanged, compared to its average volume of 1,452,638. The firm's 50 day simple moving average is $7.59 and its 200 day simple moving average is $8.04. Amneal Pharmaceuticals, Inc. has a 12-month low of $6.29 and a 12-month high of $9.48. The stock has a market cap of $2.28 billion, a price-to-earnings ratio of -10.72 and a beta of 1.17.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings results on Friday, May 2nd. The company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.05. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The firm had revenue of $695.42 million for the quarter, compared to analysts' expectations of $714.78 million. On average, equities research analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.